UNDERSTANDING ACMG GUIDELINES & CLINICAL CLASSIFICATION OF GENETIC VARIANTS
“๐๐ธ ๐ผ๐ฒ๐ท๐ฐ๐ต๐ฎ ๐ต๐ช๐ซ๐ธ๐ป๐ช๐ฝ๐ธ๐ป๐ ๐ฑ๐ช๐ผ ๐ฎ๐ท๐ธ๐พ๐ฐ๐ฑ ๐ญ๐ช๐ฝ๐ช; ๐ฌ๐ธ๐ต๐ต๐ช๐ซ๐ธ๐ป๐ช๐ฝ๐ฒ๐ฟ๐ฎ ๐ฌ๐พ๐ป๐ช๐ฝ๐ฒ๐ธ๐ท ๐ฒ๐ผ ๐ฝ๐ฑ๐ฎ ๐ฏ๐พ๐ฝ๐พ๐ป๐ฎ ๐ธ๐ฏ ๐ฐ๐ฎ๐ท๐ธ๐ถ๐ฒ๐ฌ ๐ถ๐ฎ๐ญ๐ฒ๐ฌ๐ฒ๐ท๐ฎ.” - Professor Heidi Rehm ๐งฌ Genomic medicine has moved from discovery to daily clinical decision-making. At the center of this shift are the 2015 standards from the American College of Medical Genetics & Genomics (ACMG), which established a structured framework for interpreting sequence variants. ๐น Genetic variants influence disease risk, diagnosis, prognosis, & therapeutic strategy. Without standardized interpretation, clinical decisions become inconsistent. The ACMG/AMP framework addresses this by integrating multiple evidence streams into five categories: 1. Pathogenic (Class 5) 2. Likely Pathogenic (Class 4) 3. Variant of Uncertain Significance [VUS] (Class 3) 4. Likely Benign (Class 2) 5. Benign (Class 1) This tiered system reduces interpretive subjectivity & improves reproducibility...
Comments
Post a Comment